Thursday, August 13, 2020 4:48:59 PM
(Ben Taylor announced a couple of surprises:
(1) the clients in the prostate cancer trial were mostly ASYMPTOMATIC, ahh high PSA blood tests? Biggest take-away for me was the non-adverse effects of the SM-88 on the patients
(2) Yesterday's S-3 shelf offering no more than a continuation from earlier offerings. TYME is not looking for $250 Million at this time. The original filing has to be renewed regularly.
Link to yesterday's 8K amendments to sales agreement updated with our broker (JEFFERIES LLC)Link to amended sales agreement with Jefferies LLC
(3) Explanation on HOP ES futility report. Interesting. Had a pre-agreed point to determine if trial should be terminated or were results promising enough to continue.
GLTUA
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM